查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
美國幽門螺桿菌非侵入性測試市場預測至2028年 - 按測試類型、測試方法和終端用戶分類的COVID-19影響和國家分析
市場調查報告書
商品編碼
1296776

美國幽門螺桿菌非侵入性測試市場預測至2028年 - 按測試類型、測試方法和終端用戶分類的COVID-19影響和國家分析

US Helicobacter Pylori Non-Invasive Testing Market Forecast to 2028 - Country Analysis By Test Type, Test Method, and End User
出版日期: | 出版商: The Insight Partners | 英文 112 Pages | 訂單完成後即時交付

價格

美國幽門螺桿菌非侵入性檢測市場規模預計將從2022年的2.2376億美元成長到2028年的3.0279億美元；估計從2023年到2028年將紀錄5.3%的複合成長率。美國幽門螺桿菌非侵入性檢測市場的成長歸因於幽門螺桿菌細菌感染率的增加和幽門螺桿菌非侵入性檢測市場開發活動的上升。然而，幽門螺桿菌的無症狀性阻礙了美國幽門螺桿菌非侵入性檢測市場的成長。

幽門螺桿菌是一種引起胃部感染、消化性潰瘍和胃炎的細菌。長期的細菌感染在某些情況下可能會導致胃癌。幽門螺桿菌感染在美國的西班牙裔和黑人人口中更常見，這可歸因於社會經濟因素，如低收入和識字率，家庭擁擠和大規模移民。因此，幽門螺桿菌感染患病率的增加推動了美國幽門螺桿菌非侵入性檢測市場。

幽門螺桿菌感染通常發生在有長期臨床症狀的兒童身上，如胃炎、消化性潰瘍病和胃癌。根據發表在《自然》雜誌上的一篇文章，幽門螺桿菌存在於約36%的美國人口中，對胃癌和消化性潰瘍病構成重大風險。世界衛生組織（WHO）已經承認幽門螺桿菌是導致胃癌的致癌物，在美國，胃癌是第三大最常見的胃腸道癌症。根據美國癌症協會的資料，2023年將有近26,500個新的胃癌病例和約11,130人因這種癌症類型而死亡。因此，不斷成長的癌症病例增加了美國幽門螺旋桿菌非侵入性檢測市場的成長。

此外，日益成長的老年群體對胃部疾病的易感性將大幅增加幽門螺桿菌感染的風險。衰老導致胃黏膜變薄，而使細菌透過保護性黏膜，增加老年人的疾病發病率。鑑於老年人口基數的不斷增加，《華盛頓郵報》估計，到2040年美國將有近8080萬老年公民。因此，老年人口的成長促進了美國幽門螺桿菌非侵入性檢測市場的成長。

根據美國國家衛生研究院的一份報告，2020年美國10歲以下兒童的幽門螺桿菌發病率為5%。此外，美國衛生與公眾服務部報告指出，30-40%的美國人感染了幽門螺桿菌。此外，社會經濟因素，如低收入、缺乏教育、家庭擁擠和移民，也是導緻美國西班牙裔和黑人人口感染幽門螺桿菌的原因。這些統計資料決定了美國對幽門螺桿菌非侵入性診斷的需求增加，從而推動了美國幽門螺桿菌非侵入性檢測市場的成長。

測試類型的洞察力

根據測試類型，美國幽門螺旋桿菌非侵入性檢測市場被分為尿素呼吸、糞便抗原和血清學。 2022年，尿素呼吸部分佔據了美國幽門螺桿菌非侵入性檢測市場的最大佔有率。此外，在未來幾年內，該部分預計將以最快的速度成長。尿素呼吸試驗（UBT）是檢測幽門螺桿菌感染的基本非侵入性方法之一。該測試包括根據幽門螺桿菌產生尿素酶的能力來檢測，尿素酶會將口服的尿素水解成二氧化碳和氨。這些氣體擴散到血液中，然後由肺部排泄出來。 UBTs是可靠的、低負擔的測試，在成人和兒童中得到驗證。因此，這些有助於美國幽門螺旋桿菌非侵入性檢測市場規模的成長。

根據英國癌症研究中心，慢性細菌感染會導致長期的胃部炎症，也稱為嚴重的慢性萎縮性胃炎或SCAG；長時間的胃潰瘍甚至會導致癌症。根據世界衛生組織（WHO）的資料，癌症是全世界死亡的重要原因；2021年世界上大約有190萬新的癌症病例。結直腸癌是一種常見的類型，2022年有146,589個新病例記錄。這種類型的癌症在中年和老年人口中更為流行。很少發生在40歲以下有遺傳易感性或易感條件的人中。透過適當的測試早期發現幽門螺桿菌對預防結腸癌是必要的。早期診斷對於降低與癌症有關的死亡率是非常重要的。因此，不斷上升的細菌感染病例需要進行尿素呼吸試驗，這有助於美國幽門螺桿菌非侵入性檢測市場的成長。

2020年2月，Gulf Coast Scientific公司的Pylo Plus UBT系統獲得了美國食品和藥物管理局（FDA）的批准，這是一種用於檢測幽門螺桿菌感染的13C UBT。此外，美國幽門螺桿菌非侵入性檢測市場的主要參與者形成聯盟，推出新產品並擴大其影響力。例如，在2021年，Meridian Bio簽署了一項協議，以2000萬美元的價格從大塚製藥公司收購BreahTrek。這種合作導致了UBT領域新產品的推出，並在預測期內促進了美國幽門螺旋桿菌非侵入性檢測市場的整體成長。

目錄

第一章：簡介

  • 本研究的範圍
  • Insight Partners的研究報告指南
  • 市場細分
    • 美國幽門螺桿菌（H. pylori）非侵入性測試市場- 按測試類型分類
    • 美國幽門螺桿菌（H. pylori）非侵入性測試市場- 按測試方法分類
    • 美國幽門螺桿菌（H. pylori）非侵入性檢測市場- 按終端用戶分類

第二章：美國幽門螺旋桿菌（H. pylori）非侵入性檢測市場的主要結論

第三章：研究方法

  • 涵蓋範圍
  • 二級研究
  • 初級研究

第四章：美國幽門螺旋桿菌（H. pylori）非侵入性檢測市場- 市場格局

  • 幽門螺旋桿菌（H. pylori）非侵入性檢測市場- 市場格局概述
  • PEST分析
    • 美國PEST分析
  • 專家意見
  • 美國幽門螺桿菌（H. pylori）非侵入性檢測市場，按檢測類型分類- 2022年數量（百萬）。

第五章：幽門螺桿菌（H.pylori）非侵入性檢測市場- 主要行業動態

  • 主要的市場驅動因素
    • 幽門螺桿菌感染的發病率不斷上升
    • 幽門螺桿菌非侵入性檢測的市場開發活動不斷增加
  • 主要的市場限制因素
    • 幽門螺桿菌的無症狀性
  • 主要的市場機會
    • 擴大使用基於家庭的照護端設備
  • 未來趨勢
    • 幽門螺桿菌非侵入性測試的技術進步和創新
  • 影響分析

第六章：美國幽門螺桿菌（H. pylori）非侵入式檢測市場分析

  • 美國幽門螺桿菌（H. pylori）非侵入性檢測市場收入預測和分析
  • 主要參與者的市場定位

第7章：美國幽門螺桿菌（H. pylori）非侵入性檢測市場分析- 按檢測類型分類

  • 概述
  • 尿素呼吸
  • 糞便抗原
  • 血清學

第八章：美國幽門螺桿菌（H. pylori）非侵入性檢測市場分析- 按檢測方法分類

  • 概述
  • 以實驗室為基礎
  • 照護端

第九章：美國幽門螺桿菌（H. pylori）非侵入性檢測市場分析- 按終端用戶分類

  • 概述
  • 醫院
  • 參考實驗室
  • 其他

第十章：美國幽門螺桿菌（H. pylori）非侵入性檢測市場

  • 美國

第十一章：美國幽門螺桿菌（H. pylori）非侵入性檢測市場- 行業格局

  • 概述
  • 幽門螺桿菌非侵入性檢測市場的成長策略
  • 無機成長戰略
    • 概述
  • 有機成長策略
    • 綜述

第十二章：公司簡介

  • Bioneer Corp
  • Meridian Bioscience Inc
  • Abbott Laboratories
  • Thermo Fisher Scientific Inc
  • Bio-Rad Laboratories Inc
  • Coris BioConcept SPRL
  • DiaSorin SpA
  • Sekisui Diagnostics LLC
  • CerTest Biotec SL
  • QuidelOrtho Corporation

第十三章：附錄

  • 關於Insight Partners
  • 術語表
Product Code: TIPRE00029913

The US Helicobacter Pylori Non-Invasive Testing Market size is expected to grow from US$ 223.76 million in 2022 to US$ 302.79 million by 2028; it is estimated to record a CAGR of 5.3% from 2023 to 2028. The US Helicobacter Pylori non-invasive testing market growth is attributed to the increasing prevalence of H. pylori bacterial infection and rising market development activities in H. pylori non-invasive test. However, asymptomatic nature of H. pylori is hampering the growth of the US Helicobacter Pylori Non-Invasive Testing market.

H. pylori is a bacterium causing stomach infection, peptic ulcer, and gastritis. The prolonged bacterial infection may lead to stomach cancer in some cases. The H. pylori infection is more common in the US Hispanic and black populations, which can be credited to socioeconomic factors such as low income and literacy, household crowding, and large-scale immigration. Thus, increase in prevalence of H. pylori infection fuel the US Helicobacter pylori non-invasive testing market.

The H. pylori infection usually occurs in children with long-standing clinical symptoms such as gastritis, peptic ulcer disease, and stomach cancer. According to an article published in the Nature Journal, H. pylori is present in ~36% of the US population, posing a significant risk for gastric cancer and peptic ulcer disease. The World Health Organization (WHO) has recognized H. pylori as a carcinogen that leads to gastric cancer and in the US, gastric cancer is the third most common gastrointestinal cancer. According to the American Cancer Society, nearly 26,500 new cases of stomach cancer and ~11,130 deaths will occur due to this cancer type in 2023. Thus, growing cancer cases increases the US Helicobacter pylori non-invasive testing market growth.

Further, the growing geriatric population pool susceptible to gastric diseases will substantially increase the risk of H. pylori infection. Aging leads to thinning of the stomach lining, thus allowing the bacteria to pass through the protective lining, thereby increasing the disease prevalence among older people. Given the constant increase in the geriatric population base, the Washington Post has estimated that there will be nearly 80.8 million senior citizens in the US by 2040. Thus, growing geriatric population boosts the growth of US Helicobacter pylori non-invasive testing market.

According to a report from the National Institutes of Health, there was a 5% prevalence of H. pylori in children under the age of 10 in the US in 2020. In addition, the US Department of Health and Human Services reports that 30-40% of Americans are infected with H. pylori infection. Further, socioeconomic factors, such as low income, lack of education, household crowding, and immigration contribute to H. pylori infection among Hispanic and Black populations in the US. These statistics determine an increase in the need for non-invasive diagnostics for H. pylori in the US, thus, boosting the growth of the US Helicobacter pylori non-invasive testing market.

Test Type Insights

Based on test type, the US Helicobacter pylori non-invasive testing market is categorized into urea breath, stool antigen, and serology. In 2022, the urea breath segment held the largest share of the US Helicobacter pylori non-invasive testing market. Moreover, the same segment is expected to grow at the fastest rate during the coming years. A urea breath test (UBT) is one of the essential noninvasive methods for detecting H. pylori infection. The test involves detecting H. pylori based on its ability to produce urease enzyme, which results in the hydrolysis of orally administered urea into carbon dioxide and ammonia. These gases diffuse into the blood, and the lungs then excrete them. UBTs are reliable, low-burden tests validated in adults and children. Thus, these contribute to the growth of US Helicobacter pylori non-invasive testing market size.

According to Cancer Research UK, chronic bacterial infection causes long-lasting stomach inflammation, also known as severe chronic atrophic gastritis or SCAG; prolonged stomach ulcers can even lead to cancer. According to the World Health Organization (WHO), cancer is a significant cause of death across the world; approximately 1.9 million new cancer cases were recorded in the world in 2021. Colorectal cancer is a common type, with 146,589 new cases recorded in 2022. This type of cancer is more prevalent in middle-aged and geriatric populations. It rarely occurs among people aged less than 40 with genetic predisposition or predisposing conditions. The early detection of H. pylori via appropriate tests is necessary to prevent colorectal cancer. Early diagnosis is pivotal to reducing cancer-related mortality rates. Thus, the rising cases of bacterial infections are necessitating urea breath tests which contributes to the growth of US Helicobacter Pylori non-invasive testing market.

In February 2020, Gulf Coast Scientific received approval from the US Food and Drug Administration (FDA) for the Pylo Plus UBT System, a 13C UBT for the detection of H. pylori infection. In addition, key players in the US Helicobacter pylori non-invasive testing market form alliances to introduce new products and expand their presence. For instance, in 2021, Meridian Bio signed an agreement to acquire BreahTrek from Otsuka Pharmaceutical for US$ 20 million. Such collaborations led to the new product launches in the UBT segment and contribute the overall growth of US Helicobacter pylori non-invasive testing market during the forecast period.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the US H. pylori non-invasive testing market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the US H. pylori non-invasive testing market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 US Helicobacter pylori (H. pylori) Non-Invasive Testing Market - By Test Type
    • 1.3.2 US Helicobacter pylori (H. pylori) Non-Invasive Testing Market - By Test Method
    • 1.3.3 US Helicobacter pylori (H. pylori) Non-Invasive Testing Market - By End User

2. US Helicobacter pylori (H. pylori) Non-invasive Testing Market Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. US Helicobacter pylori (H. pylori) Non-invasive Testing Market - Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 US PEST Analysis
  • 4.3 Experts Opinion
  • 4.4 United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market, by Test Type - Volume 2022 (Million)

5. Helicobacter pylori (H. pylori ) Non-Invasive Testing Market - Key Industry Dynamics

  • 5.1 Key Market Drivers
    • 5.1.1 Increasing Prevalence of H. pylori Bacterial Infection
    • 5.1.2 Rising Market Development Activities in H. pylori Non-Invasive Testing
  • 5.2 Key Market Restraints
    • 5.2.1 Asymptomatic Nature of H. pylori
  • 5.3 Key Market Opportunities
    • 5.3.1 Increasing Use of Home-Based Point of Care Devices
  • 5.4 Future Trends
    • 5.4.1 Technological Advancements and Innovations in H. pylori Non-Invasive Testing
  • 5.5 Impact Analysis

6. US Helicobacter pylori (H. pylori) Non-Invasive Testing Market Analysis

  • 6.1 US Helicobacter pylori (H. pylori) Non-invasive Testing Market Revenue Forecast and Analysis
  • 6.2 Market Positioning of Key Players

7. United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market Analysis - by Test Type

  • 7.1 Overview
  • 7.2 United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market, by Test Type - Revenue and Forecast to 2028 (US$ Million)
  • 7.3 Urea Breath
    • 7.3.1 Overview
    • 7.3.2 Urea Breath: United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.4 Stool Antigen
    • 7.4.1 Overview
    • 7.4.2 Stool Antigen: United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.5 Serology
    • 7.5.1 Overview
    • 7.5.2 Serology: United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market - Revenue and Forecast to 2028 (US$ Million)

8. United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market Analysis - by Test Method

  • 8.1 Overview
  • 8.2 United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market, by Test Method - Revenue and Forecast to 2028 (US$ Million)
  • 8.3 Laboratory Based
    • 8.3.1 Overview
    • 8.3.2 Laboratory Based: Helicobacter pylori (H. pylori) Non-Invasive Testing Market- Revenue and Forecast to 2028 (US$ Million)
  • 8.4 Point of Care
    • 8.4.1 Overview
    • 8.4.2 Point of Care: Helicobacter pylori (H. pylori) Non-Invasive Testing Market- Revenue and Forecast to 2028 (US$ Million)

9. United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market Analysis - by End User

  • 9.1 Overview
  • 9.2 United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market, by End User - Revenue and Forecast to 2028 (US$ Million)
  • 9.3 Hospitals
    • 9.3.1 Overview
    • 9.3.2 Hospitals: United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market - Revenue and Forecast to 2028 (US$ Million)
  • 9.4 Reference Laboratories
    • 9.4.1 Overview
    • 9.4.2 Reference Laboratories: United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market - Revenue and Forecast to 2028 (US$ Million)
  • 9.5 Others
    • 9.5.1 Overview
    • 9.5.2 Others: United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market - Revenue and Forecast to 2028 (US$ Million)

10. United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market: Impact Assessment of COVID-19 Pandemic

  • 10.1 US: Impact Assessment of COVID-19 Pandemic

11. US Helicobacter pylori (H. pylori) Non-Invasive Testing Market - Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in the Helicobacter pylori Non-Invasive Testing Market
  • 11.3 Inorganic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Organic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 Bioneer Corp
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Meridian Bioscience Inc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Abbott Laboratories
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Thermo Fisher Scientific Inc
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Bio-Rad Laboratories Inc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Coris BioConcept SPRL
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 DiaSorin SpA
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Sekisui Diagnostics LLC
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 CerTest Biotec SL
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 QuidelOrtho Corporation
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners
  • 13.2 Glossary of Terms

List Of Tables

  • Table 1. United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market, by Test Type - Volume 2022 (Million)
  • Table 2. United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market, by Test Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 3. United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market, by Test Method - Revenue and Forecast to 2028 (US$ Million)
  • Table 4. United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market, by End User - Revenue and Forecast to 2028 (US$ Million)
  • Table 5. Recent Inorganic Growth Strategies in the H. pylori Non-Invasive Testing Market
  • Table 6. Recent Organic Growth Strategies in the H. pylori Non-Invasive Testing Market
  • Table 7. Glossary of Terms

List Of Figures

  • Figure 1. Helicobacter Pylori (H. pylori ) Non-Invasive Testing Market Segmentation
  • Figure 2. US Helicobacter pylori (H. pylori) Non-invasive Testing Market Overview
  • Figure 3. Urea Breath Segment Held Largest Share of Test Type Segment in Helicobacter pylori (H. pylori) Non-invasive Testing Market
  • Figure 4. US Helicobacter pylori (H. pylori) Non-invasive Testing Market, Industry Landscape
  • Figure 5. US: PEST Analysis
  • Figure 6. Experts Opinion
  • Figure 7. Helicobacter pylori Non-Invasive Testing Market Impact Analysis of Driver and Restraints
  • Figure 8. US Helicobacter pylori (H. pylori) Non-invasive Testing Market- Revenue Forecast and Analysis - 2020 - 2028
  • Figure 9. Market Positioning of Key Players in US Helicobacter pylori (H. pylori) Non-Invasive Testing Market
  • Figure 10. United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market, by Type, 2022 & 2028 (%)
  • Figure 11. Urea Breath: United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 12. Stool Antigen: United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 13. Serology: United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 14. United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market, by Test Method, 2022 & 2028 (%)
  • Figure 15. Laboratory Based: Helicobacter pylori (H. pylori) Non-Invasive Testing Market- Revenue and Forecast to 2028 (US$ Million)
  • Figure 16. Point of Care: Helicobacter pylori (H. pylori) Non-Invasive Testing Market- Revenue and Forecast to 2028 (US$ Million)
  • Figure 17. United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market, by End User, 2022 & 2028 (%)
  • Figure 18. Hospitals: United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 19. Specialty Clinics: United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 20. Others: United States Helicobacter pylori (H. pylori) Non-Invasive Testing Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 21. Impact of COVID-19 Pandemic on US Helicobacter pylori (H. pylori) Non-Invasive Testing Market
  • Figure 22. Growth Strategies in the Helicobacter pylori Non-Invasive Testing Market